Dr. Jennifer Cultrera, MD
It is imperative to discover novel agents to improve patient survival and offer new treatment options to patients with hematologic malignancies. B-cell non-Hodgkin?s lymphomas are a diverse group of disorders with significant biological and clinical heterogeneity. Albeit several subtypes respond well to traditional therapy; high grade forms of the disease often relapse. It is imperative to discover novel therapeutics to help improve patient survival to offer patients new treatment options.